Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Capital Leases (2017 - 2023)

Vistagen Therapeutics (VTGN) has disclosed Capital Leases for 9 consecutive years, with $6000.0 as the latest value for Q4 2023.

  • Quarterly Capital Leases fell 24.05% to $6000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $6000.0 through Dec 2023, down 24.05% year-over-year, with the annual reading at $7400.0 for FY2023, N/A changed from the prior year.
  • Capital Leases hit $6000.0 in Q4 2023 for Vistagen Therapeutics, down from $6500.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $8700.0 in Q2 2022 to a low of $300.0 in Q4 2020.
  • Historically, Capital Leases has averaged $5185.7 across 4 years, with a median of $5750.0 in 2019.
  • Biggest five-year swings in Capital Leases: crashed 92.31% in 2020 and later decreased 19.54% in 2023.
  • Year by year, Capital Leases stood at $3900.0 in 2019, then plummeted by 92.31% to $300.0 in 2020, then soared by 2533.33% to $7900.0 in 2022, then fell by 24.05% to $6000.0 in 2023.
  • Business Quant data shows Capital Leases for VTGN at $6000.0 in Q4 2023, $6500.0 in Q3 2023, and $7000.0 in Q2 2023.